Summit Therapeutics’ Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

All NewsMay 30, 2025

Summit Therapeutics’ Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent